Model for End-Stage Liver Disease Correlates with Disease Relapse and Death of Patients with Merkel Cell Carcinoma.
APRI-score
De Ritis
MCC
MELD
biomarkers
carcinoma
liver
neuroendocrine
skin cancer
tumor metabolism
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Jun 2023
15 Jun 2023
Historique:
received:
02
05
2023
revised:
12
06
2023
accepted:
13
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Merkel cell carcinoma (MCC) is a highly malignant skin tumor that occurs mainly in elderly and/or immunosuppressed patients. MCC prognosis has been significantly improved by the introduction of immune checkpoint inhibitor treatment. Recently, blood-based biomarkers have been investigated that can potentially predict the outcome of MCC patients. In this context, parameters of liver scores have not yet been investigated. We retrospectively recruited 47 MCC patients with available relevant laboratory data at primary diagnosis. At this time, we investigated blood-based scores as follows: model for end-stage liver disease (MELD), aspartate aminotransferase/platelet count ratio index (APRI), and the alanine transaminase/aspartate aminotransferase ratio (De Ritis ratio). MCC relapse was negatively correlated with the De Ritis score (r = -0.3,
Identifiants
pubmed: 37370805
pii: cancers15123195
doi: 10.3390/cancers15123195
pmc: PMC10296200
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Manag Res. 2019 Feb 12;11:1401-1414
pubmed: 30863151
Biomark Med. 2020 Oct;14(15):1453-1460
pubmed: 33151096
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562643
Ann Hepatol. 2008 Oct-Dec;7(4):350-7
pubmed: 19034235
Int J Clin Pract. 2021 Apr;75(4):e13743
pubmed: 32991771
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
Aktuelle Urol. 2022 Dec;53(6):540-544
pubmed: 36302549
J Dtsch Dermatol Ges. 2023 Mar;21(3):305-320
pubmed: 36929552
Neoplasia. 2018 Dec;20(12):1227-1235
pubmed: 30414538
J Natl Cancer Inst. 2010 Jun 2;102(11):793-801
pubmed: 20424236
Cancer Med. 2022 Feb;11(3):798-814
pubmed: 34850600
Semin Liver Dis. 2019 Nov;39(4):403-413
pubmed: 31242526
Onco Targets Ther. 2019 Jul 02;12:5201-5213
pubmed: 31308692
J Am Acad Dermatol. 2002 May;46(5):661-6
pubmed: 12004304
Br J Dermatol. 2022 Nov;187(5):806-808
pubmed: 35762290
Compr Physiol. 2014 Jan;4(1):177-97
pubmed: 24692138
World J Urol. 2021 Jun;39(6):1961-1968
pubmed: 32808107
J Cancer Res Clin Oncol. 2022 Nov;148(11):3183-3189
pubmed: 35098389
Ann Surg Oncol. 2011 Sep;18(9):2529-37
pubmed: 21431988
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Viruses. 2022 Oct 26;14(11):
pubmed: 36366457
Int Urol Nephrol. 2017 Aug;49(8):1391-1398
pubmed: 28550473
Mol Cancer. 2017 Dec 02;16(1):176
pubmed: 29197379
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Nat Rev Clin Oncol. 2018 Dec;15(12):763-776
pubmed: 30287935
Diagnostics (Basel). 2020 Nov 19;10(11):
pubmed: 33228184
S Afr Med J. 2011 Jun 27;101(7):477-80
pubmed: 21920102
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546